How to Read Clinical Trial Data: A Practical Guide for Non-Scientists

Why This Matters

Clinical trial results are the foundation of evidence-based medicine. When a new study is published, whether for retatrutide or any other therapeutic, the quality of public discourse depends on how well people understand what the numbers actually mean. This guide explains the key concepts needed to critically evaluate clinical trial results, using examples from metabolic medicine to make the concepts concrete.

Understanding Study Design

Randomization

In a randomized trial, participants are assigned to treatment groups by chance (like flipping a coin), not by choice. This is critical because it ensures that the treatment groups are comparable at baseline. Without randomization, healthier or more motivated participants might preferentially end up in the active treatment group, making it impossible to determine whether improvements are due to the drug or to the participants’ characteristics.

Blinding

Double-blind studies mean that neither the participants nor the investigators know who is receiving active treatment versus placebo. This prevents bias in both patient behavior (trying harder if they know they are on the drug) and investigator assessment (unconsciously scoring outcomes more favorably for the active group). In injectable drug trials, the placebo is typically a matching injection without the active compound.

Control Groups

A control group provides the baseline against which the treatment effect is measured. In placebo-controlled trials, the control group receives an inactive substance. In active-comparator trials, it receives an existing therapy. The choice of control group profoundly affects how results are interpreted.

Key Endpoint Concepts

Primary vs. Secondary Endpoints

The primary endpoint is the single most important outcome the trial is designed to detect. It determines the sample size, drives the statistical analysis plan, and is the basis for regulatory decisions. For obesity trials, this is typically the percentage change in body weight.

Secondary endpoints provide additional information. They might include the proportion of participants achieving specific weight loss thresholds, changes in blood pressure or cholesterol, or patient-reported quality of life measures. Secondary endpoints are important but carry less statistical weight because trials are not specifically powered to detect them, and testing multiple secondary endpoints increases the risk of false-positive findings.

Estimands: What Exactly Are We Measuring?

Modern trial reporting distinguishes between different “estimands,” or ways of defining the treatment effect:

• Treatment policy estimand: Includes all participants regardless of whether they completed treatment or adhered to the protocol. This estimates the effect of being assigned to the treatment. It is the more conservative estimate.
• Efficacy estimand (or “trial product estimand”): Estimates the effect in participants who continued treatment as prescribed. This tends to show larger effects because it excludes those who dropped out (who may have been less responsive or less tolerant).

When comparing results across trials, it is essential to confirm that the same estimand is being used. Mixing treatment policy and efficacy estimand results in the same comparison table is misleading.

Interpreting the Numbers

Statistical Significance

A result is “statistically significant” if the probability that it occurred by chance alone is below a predefined threshold, typically p < 0.05. This means there is less than a 5% probability that the observed difference between treatment and placebo is due to random variation.

Statistical significance tells you that a difference probably exists. It does not tell you whether the difference is large enough to matter clinically. A trial with thousands of participants can detect tiny differences that are statistically significant but clinically irrelevant.

Clinical Significance

Clinical significance asks whether the treatment effect is large enough to produce meaningful benefit for patients. In obesity medicine, the FDA considers 5% mean weight loss as the threshold for clinical significance. A 1% weight loss, even if statistically significant, would not be considered clinically meaningful.

For glycemic control, an HbA1c reduction of 0.3-0.4% is generally considered the minimum clinically meaningful difference, while reductions of 1% or more are considered robust.

Effect Size vs. Relative Effect

Pay attention to whether results are reported as absolute or relative values:

• Absolute: “Liver fat decreased from 20% to 3.6%” (clear, interpretable)
• Relative: “Liver fat decreased by 82%” (sounds more impressive but requires knowing the starting point)

Both are valid, but relative changes can be misleading without context. An 82% reduction from 20% liver fat is dramatically different from an 82% reduction from 2% liver fat.

Confidence Intervals

A confidence interval (CI) provides a range within which the true treatment effect likely falls. For example, “mean weight loss: 24.2% (95% CI: 21.5-26.9)” means we are 95% confident that the true mean weight loss lies somewhere between 21.5% and 26.9%.

Wider confidence intervals indicate more uncertainty, often due to smaller sample sizes. Narrow confidence intervals indicate more precise estimates. If a confidence interval crosses zero (for a difference measure) or crosses 1.0 (for a ratio measure), the result is not statistically significant.

Common Pitfalls in Interpretation

Cross-Trial Comparisons

Comparing results between different trials is one of the most common and most problematic practices in medical discussion. Trials differ in:

• Patient populations (age, BMI, ethnicity, comorbidities)
• Treatment duration
• Background therapies
• Endpoint definitions
• Statistical methods
• Geographic location and clinical practice patterns

When someone says “Drug A produced 24% weight loss and Drug B produced 15%, so Drug A is better,” they are making a cross-trial comparison that may or may not be valid. Only head-to-head trials within the same study can reliably compare two treatments.

Phase 2 vs. Phase 3 Results

Phase 2 trials are smaller and often enroll more carefully selected participants. Effect sizes in Phase 2 trials sometimes attenuate (decrease) in Phase 3 trials due to the larger, more diverse population and more rigorous trial conditions. Treating Phase 2 results as final evidence is premature.

Publication Bias

Positive results are more likely to be published than negative results. This means the published literature may overrepresent the benefits of treatments. Looking for registered trials on ClinicalTrials.gov can help identify studies that were conducted but not published.

Surrogate vs. Clinical Endpoints

A surrogate endpoint is a measurable marker that is expected to predict a clinical outcome. For example, HbA1c is a surrogate endpoint for diabetes complications; it does not directly measure whether patients develop kidney disease or lose vision, but improvements in HbA1c are strongly correlated with reduced complication rates.

Weight loss itself is a surrogate endpoint for the clinical outcomes that matter to patients: reduced cardiovascular events, improved mobility, better quality of life, and longer survival. While substantial weight loss is associated with these clinical benefits, the relationship is not automatic, and cardiovascular outcomes trials remain important.

Applying These Concepts

When you encounter clinical trial results, consider asking:

1. Was it randomized and controlled? If not, the results are less reliable.
2. How many participants? Larger trials produce more reliable estimates.
3. How long was treatment? Chronic disease treatments need long-term data.
4. What was the primary endpoint? Focus on what the trial was designed to measure.
5. Was it statistically significant AND clinically meaningful?
6. What estimand was used? Treatment policy or efficacy estimand?
7. What are the confidence intervals? How precise is the estimate?
8. Is this Phase 2 or Phase 3? Phase 2 results require confirmation.
9. Am I making cross-trial comparisons? If so, proceed with extreme caution.
10. What does the safety data show? Efficacy without safety is not useful.

These questions apply to retatrutide data and to any other clinical trial results you encounter. Critical evaluation of evidence is not about being skeptical; it is about being rigorous in understanding what the data can and cannot tell us.